← Human Trials & Peer-Reviewed Studies
Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients
Plain-language guide to PMID 30520243 (2019): multicenter randomized controlled trial study of Exenatide.
Key Facts
- PMID
- 30520243
- Journal
- Journal of diabetes
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Deng H et al. (8 authors)
- DOI
- 10.1111/1753-0407.12883
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exenatide, published as a randomized controlled trial.
This study evaluated the effects of exenatide monotherapy on glycemic control and weight change in normal-weight, overweight, and obese patients with newly diagnosed type 2 diabetes (T2D).
Who Took Part
The age groups tagged for this paper are middle-aged adults, both men and women.
In this multicenter prospective study, 29 normal-weight, 54 overweight, and 27 obese newly diagnosed and drug-naïve patients with T2D were treated with exenatide for 48 weeks.
How the Study Was Run
The researchers set it up as a randomized and multicenter study.
Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Running at several centres spread the Exenatide study over different clinics and patient groups.
A time span of 48 weeks appears in the methods.
Other endpoints included comparisons of the effects of exenatide on fasting plasma glucose (FPG), postprandial plasma glucose (PPG), body weight, and other metabolic indices.
What Was Measured
This study evaluated the effects of exenatide monotherapy on glycemic control and weight change in normal-weight, overweight, and obese patients with newly diagnosed type 2 diabetes (T2D).
Topics PubMed links to this paper include Biomarkers, Blood Glucose, Body Mass Index, Case-Control Studies, Diabetes Mellitus, Type 2, Exenatide and Glycated Hemoglobin.
Author keywords: 2型糖尿病, body weight, type 2 diabetes, 体重 and 艾塞那肽.
What This Means in Plain Language
The paper is a randomized and multicenter study of Exenatide over 48 weeks.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (Journal of diabetes), a journal based in Australia.
More context: the Exenatide compound page, all human trials.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.